- Annovis shares sank by ~60% yesterday after the company presented additional data from a study of its lead drug Posiphen in 14 Alzheimer's and 14 Parkinson's patients.
- Promising data released in May had shown a 4.4 point increase in the cognitive scoring system ADAS-Cog11. Better than Aduhelm, and Cassava's Simufilam albeit after a very short period.
- The new data failed to live up to the hype, failing to outperform placebo based on two other cognitive scoring systems.
- It's bad news for Annovis, placing the company's ambition to launch two Phase 3 trials in AD and PD in jeopardy, but more data will soon be available and it may be too early to judge the company.
- The reality may be that Posiphen is neither a wonder drug nor a busted flush, but it's based on sound scientific investigation and the promising thesis that targeting Alzheimer's upstream of amyloid beta and tau is the way forward.
For further details see:
Tanking On Poor Alzheimer's Data Doesn't Make Annovis Bio A Busted Flush